NEWS UPDATE: FDA Approves New Oral Treatment for Relapsing Forms of MS

[johnMSAA]

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the United States Food and Drug Administration (FDA) approved Ponvory™ (ponesimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults — including clinically isolated syndrome, relapsing-remitting, and active secondary-progressive forms of MS.

This new disease-modifying therapy is taken orally (by mouth) once daily and has been shown to reduce annual relapse rates and reduce disease activity as shown on magnetic resonance imaging (MRI).

For more information, please see MSAA’s News Item, “FDA Approves Ponvory™ for the Treatment of Relapsing Forms of MS" via the following link:

mymsaa.org/news/fda-approve...

- John, MSAA